*This article is an automatic translation of the original article, provided here for your convenience. Read the original article. After perindopril, citalopram and fentanyl, the Commission sanctions a new practice of pay-for-delay. This time it concerns modafinil, a drug used for the treatment of excessive daytime sleepiness, particularly in connection with narcolepsy and marketed under the brand name "Provigil". On November 26, 2020, it announced which, almost ten years after the opening of the formal investigation
ALERTS: CARTELS - EUROPEAN UNION - PHARMACEUTICAL INDUSTRY – PAY-FOR-DELAY - SANCTIONS
Pay-for-delay: The European Commission fines two pharmaceutical companies €60.5 million for a pay-for-delay practice (Teva, Cephalon)
Access to this article is restricted to subscribers
Already Subscribed? Sign-in
Access to this article is restricted to subscribers.
Read one article for free
Sign-up to read this article for free and discover our services.